RxDoctor Payments Data

Noah Levit

Dermatopathology · Hamden, CTNPI 1710334420

Payments from drug & device makers

$549,650in general payments, 2019–2025

Across 1,151 payments — averaging $477.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$136K
  • Regeneron Healthcare Solutions, Inc.$130K
  • Sanofi$88K
  • Arcutis Biotherapeutics, Inc.$82K
  • Galderma Laboratories, L.p.$34K
  • Pfizer$33K
  • plus $45K from 21 others
$24,433in research payments, 2019–2025

Across 27 payments — averaging $904.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$24K

What the payments were for

  • Consulting fees$129,91624%
  • Speaking & faculty fees$337,79861%
  • Travel & lodging$56,55410%
  • Food & beverage$24,6424%
  • Education$7400%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few dermatopathology providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$127,017
Medicare patients
515
Services billed
2,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab38$153,755
RinvoqUpadacitinib12$89,547
Metronidazole54$4,608
Tacrolimus18$2,949
Fluorouracil36$2,541
Triamcinolone Acetonide144$2,034
Clobetasol Propionate72$1,770
Fluocinonide45$1,547
Ketoconazole154$1,529
Ciclopirox52$1,503
Clindamycin Phosphate55$1,460
Mometasone Furoate90$1,394
Desonide45$1,391
Hydrocortisone76$1,293
Doxycycline Hyclate49$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$10,081$89,54712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few dermatopathology providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other dermatopathology in Hamden

Where these figures come from

Is this you, or does something look wrong? →